Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases (NAGKC 12-01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01731704 |
Recruitment Status
:
Withdrawn
(Insufficient staff)
First Posted
: November 22, 2012
Last Update Posted
: March 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Metastases | Radiation: Stereotactic radiosurgery (SRS) Radiation: Whole brain radiation therapy (WBRT) | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Controlled Study Of Neurocognitive Outcomes In Patients With Five Or More Brain Metastases Treated With Radiosurgery Or Whole-Brain Radiotherapy |
Study Start Date : | December 2012 |
Actual Primary Completion Date : | October 26, 2015 |
Estimated Study Completion Date : | December 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Stereotactic Radiosurgery (SRS)
Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
|
Radiation: Stereotactic radiosurgery (SRS)
Other Name: Gamma knife Perfexion radiosurgical device
|
Active Comparator: Whole Brain Radiation Therapy (WBRT)
whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
|
Radiation: Whole brain radiation therapy (WBRT)
External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
|
- To compare the relative change in neurocognitive outcomes (change in oNCF z-score) between baseline and 6 months for surviving patients in upfront WBRT vs. SRS treatment groups. [ Time Frame: Every 3 months for 12 months ]
All participants will be asked to complete:
- Online brain function testing: Complete a short 20-minute online brain function (cognitive) assessment every 2 weeks (twice per month, at least 10-14 days apart).
- Quality of Life Questionnaire: Complete a self-reported (if patient) and caregiver quality of life questionnaires every 10-12 weeks (2.5-3 months). These questionnaires take approximately 15-20 minutes to complete and can be done online or in clinic during follow-up visits.
- To compare the relative change in neurocognitive outcomes (change in oNCF z-score) between baseline and 12 months for surviving patients in upfront WBRT vs. SRS treatment groups. [ Time Frame: Every 10-12 weeks for 12 months after treatment ]
- Neurocognitive function, 12-months post whole-brain radiation therapy (WBRT)/stereotactic radiosurgery (SRS)specifically the Gamma Knife (GK) system, treatment as measured by the online neurocognitive function (oNCF) composite z-score.
- Neurocognitive function at all time points as measured by the online neurocognitive function (oNCF) composite z-score.
- To compare the relative impact of initial therapy on patients' quality of life (QoL) as measured by caregiver assessments [ Time Frame: Every 10-12 weeks for 12 months after treatment ]• Quality of life (patient-reported measures) as measured by Beck Depression Inventory, Beck Anxiety Inventory, FACT-Br, FACT-Cog, Fatigue Severity Scale, EuroQol(EQ5D), EORTC-BN20, and QOL-30.
- To compare the relative impact of initial therapy on patients' quality of life (QoL) as measured by caregiver assessments [ Time Frame: Every 10-12 months ]Quality of life as measured by caregiver assessments including Frontal Systems Behavior Scale, Neuropsychiatric Inventory, Functional Activities Questionnaire, and Everyday Cognition Questionnaire.
- To estimate consistency and change in z-scores for oNCF assessments over all study endpoints in surviving patients treated with upfront whole brain radiation therapy (WBRT) vs. stereotactic radiosurgery (SRS). [ Time Frame: Every 10-12 months ]
- To compare proportions of patients in the two treatment groups that require salvage therapy as a function of systemic disease control (controlled vs. uncontrolled). [ Time Frame: 3, 6, 9, and 12 months ]
- To compare the overall survival between patients in upfront whole brain radiation therapy (WBRT) vs. stereotactic radiosurgery (SRS) treatment groups [ Time Frame: baseline to study completion ]
- Cost analysis [ Time Frame: Prior to treatment up to 12 months after treatment is complete ]To determine what healthcare cost data can be collected in patients with metastatic disease within a context of a multi-institutional clinical trial.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration. If the original histologic proof of malignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease).
- If an open biopsy is performed, the patient must be at least one week post biopsy. This requirement does not apply to patients who undergo stereotactic biopsies.
- Patients with ≥5 measurable brain metastases on a diagnostic-quality contrast-enhanced magnetic resonance imaging (MRI) obtained within 30 days prior to registration.
- Patients with ≤10 cc largest tumor volume, and ≤15 cc total tumor volume.
- History/physical examination within 30 days prior to registration.
- Age ≥18 years.
- Karnofsky performance status ≥70 (RTOG recursive partitioning analysis (RPA) Class I & II).
- Minimum pre-treatment oNCF score ≥70.
- Patients must provide study-specific informed consent prior to study entry.
- Women of child-bearing age must have a negative, quantitative serum pregnancy test ≤14 days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation).
- Patients must be able to speak and read English fluently (required for the use of online NCF testing).
- Patients must demonstrate basic computer literacy skills and have access to an internet terminal (required for the use of online NCF testing).
Exclusion Criteria:
- Clinical (e.g. multiple new cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease.
- Patients with measurable brain metastasis(es) resulting from small cell lung cancer and/or germ cell malignancy.
- No documentation of prior cytotoxic or other therapy for malignancy if such therapy was previously received. Note: This does not apply to patients with synchronous metastases at initial diagnosis.
- Contraindication to MR imaging, such as implanted metal devices or foreign bodies, severe claustrophobia, or contraindications to contrast agent administration.
-
Estimated glomerular filtration rate (eGFR) <60 within 6 weeks prior to registration. • Prior radiation therapy to the brain. • Severe, active co-morbidity, defined as follows:
- Unstable angina, and/or congestive heart failure requiring hospitalization within the last 6 months.
- Transmural myocardial infarction within the last 6 months. - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization, or precluding study therapy at the time of registration.
- Uncontrolled, clinically significant cardiac arrhythmias. - Radiologic or clinical evidence of hydrocephalus, or history of previously treated hydrocephalus.
- Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study is potentially teratogenic

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731704
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94143 |
Study Chair: | Igor J Barani, MD | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT01731704 History of Changes |
Other Study ID Numbers: |
121010/12-01 |
First Posted: | November 22, 2012 Key Record Dates |
Last Update Posted: | March 14, 2017 |
Last Verified: | March 2017 |
Keywords provided by University of California, San Francisco:
5 or more brain metastases proven diagnosis of a non-hematopoietic malignancy non-small cell lung cancer or germ cell malignancy |
Additional relevant MeSH terms:
Neoplasm Metastasis Neoplasms, Second Primary Brain Neoplasms Neoplastic Processes Neoplasms Pathologic Processes |
Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |